Clay Siegall has several professional acolades behind his name. He holds a B.S. degree from George Washington University in Zoology and a Ph.D. in Genetics from the University of Maryland. Furthermore, Dr. Siegall is published in over 70 papers and journals, has 15 patents and is active in the field of research in targeted therapies for cancer treatment.
Prior to co-founding the biotech company Seattle Genetics in 1998, Dr. Siegall worked in areas of research with The National Cancer Institute and Bristol-Myers Squibb. Presently, Dr. Siegall is nearing two decades in leadership capacity with Seattle Genetics. He is Chairman of its board, Chief Executive Officer and company President. Dr. Siegall too, has aided the company in capital fund raising since its inception. The company financially stands at the brink of being a key player in the cancer treatment industry from its partnerships and its financial status.
In a recent interview, Dr. Siegall told that Seattle Genetics earns its income by (1) Selling the drugs it develops; (2) Production partnerships; (3) Licensing of technologies developed in-house.
Dr. Clay Siegall admits sporadic speculative moments during the first couple years of the company’s existence. However, a talented sales staff and unique product line were combined to help solidify the company’s identity and future. Dr. Siegall attributes the company’s marketing success to be due to hard work. He sees education, background, and one’s connections as secondary. He credits work habit and focus are the components that make for success. Unique to Seattle Genetics is the approach to take perspective patrons out for dinner and engage in intense negotiation.
In the recent past Dr. Siegall received awards for his contributions to the fields of medicine and science.
– The University of Maryland Alumnus of the Year Award; he was recognized for his contributions to Math, Computers and Natural Sciences, 2013.
– Pacific Northwest Ernst and Young Entrepreneur of the Year, 2012.
Dr. Siegall continues to be actively involved in promoting targeted therapies for treating cancer and was instrumental in the FDA approving Adcetris in 2011. He foresees a time nearing when targeted therapies will supplant systemic chemotherapy.